Increased circulating adiponectin in males with chronic HCV hepatitis

Elena Canavesi, Marianna Porzio, Massimiliano Ruscica, Raffaela Rametta, Chiara Macchi, Serena Pelusi, Anna Ludovica Fracanzani, Paola Dongiovanni, Silvia Fargion, Paolo Magni, Luca Valenti

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background Increased levels of adiponectin, a major adipokine with insulin sensitizing properties showing a strong sexual dimorphism, have been reported in individuals with chronic HCV infection (CHC), but data are limited by small samples and lack of control for the genetic background and hepatic fibrosis. The aim of this study was to compare adiponectin levels between CHC patients and accurately matched controls. Methods We considered 184 CHC patients, matched (1:1) for age, gender, body mass index, and Adiponectin genotype (ADIPOQ) with healthy individuals. To control for the severity of liver disease, a second control group consisting of 95 patients with histological nonalcoholic fatty liver disease (NAFLD) further matched (1:1) for severe fibrosis was exploited. ADIPOQ genotype was evaluated by Taqman assays, serum adiponectin measured by ELISA. Results Serum adiponectin was higher in CHC patients than in healthy individuals (9.0 ± 5.0 μg/ml vs. 7.3 ± 4.0 μg/ml; p = 0.001; adjusted estimate + 1.8, 1.7-2.9; p = 0.001), and than in NAFLD patients (8.3 ± 4.5 μg/ml vs. 6.0 ± 4.2 μg/ml; p <0.001; adjusted estimate + 0.8, 0.2-1.4, p = 0.006). After stratification for sex, serum adiponectin was higher in males with CHC than in healthy individuals and NAFLD patients (p <0.005 for both), whereas the difference was not significant in females. Conclusions CHC is associated with increased serum adiponectin independently of age, body mass, diabetes, ADIPOQ genotype, and of severe liver fibrosis, particularly in men.

Original languageEnglish
Pages (from-to)635-639
Number of pages5
JournalEuropean Journal of Internal Medicine
Volume26
Issue number8
DOIs
Publication statusPublished - Oct 1 2015

Fingerprint

Adiponectin
Chronic Hepatitis
Infection
Genotype
Serum
Fibrosis
Adipokines
Sex Characteristics
Liver Cirrhosis
Liver Diseases
Body Mass Index
Enzyme-Linked Immunosorbent Assay
Insulin
Control Groups
Liver
Non-alcoholic Fatty Liver Disease

Keywords

  • Adipokines
  • Adiponectin
  • Gender
  • Hepatic fibrosis
  • Hepatitis C virus
  • Nonalcoholic fatty liver disease

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Increased circulating adiponectin in males with chronic HCV hepatitis. / Canavesi, Elena; Porzio, Marianna; Ruscica, Massimiliano; Rametta, Raffaela; Macchi, Chiara; Pelusi, Serena; Fracanzani, Anna Ludovica; Dongiovanni, Paola; Fargion, Silvia; Magni, Paolo; Valenti, Luca.

In: European Journal of Internal Medicine, Vol. 26, No. 8, 01.10.2015, p. 635-639.

Research output: Contribution to journalArticle

Canavesi, Elena ; Porzio, Marianna ; Ruscica, Massimiliano ; Rametta, Raffaela ; Macchi, Chiara ; Pelusi, Serena ; Fracanzani, Anna Ludovica ; Dongiovanni, Paola ; Fargion, Silvia ; Magni, Paolo ; Valenti, Luca. / Increased circulating adiponectin in males with chronic HCV hepatitis. In: European Journal of Internal Medicine. 2015 ; Vol. 26, No. 8. pp. 635-639.
@article{62f8ad36f0c9425b8bfeeef41be36982,
title = "Increased circulating adiponectin in males with chronic HCV hepatitis",
abstract = "Background Increased levels of adiponectin, a major adipokine with insulin sensitizing properties showing a strong sexual dimorphism, have been reported in individuals with chronic HCV infection (CHC), but data are limited by small samples and lack of control for the genetic background and hepatic fibrosis. The aim of this study was to compare adiponectin levels between CHC patients and accurately matched controls. Methods We considered 184 CHC patients, matched (1:1) for age, gender, body mass index, and Adiponectin genotype (ADIPOQ) with healthy individuals. To control for the severity of liver disease, a second control group consisting of 95 patients with histological nonalcoholic fatty liver disease (NAFLD) further matched (1:1) for severe fibrosis was exploited. ADIPOQ genotype was evaluated by Taqman assays, serum adiponectin measured by ELISA. Results Serum adiponectin was higher in CHC patients than in healthy individuals (9.0 ± 5.0 μg/ml vs. 7.3 ± 4.0 μg/ml; p = 0.001; adjusted estimate + 1.8, 1.7-2.9; p = 0.001), and than in NAFLD patients (8.3 ± 4.5 μg/ml vs. 6.0 ± 4.2 μg/ml; p <0.001; adjusted estimate + 0.8, 0.2-1.4, p = 0.006). After stratification for sex, serum adiponectin was higher in males with CHC than in healthy individuals and NAFLD patients (p <0.005 for both), whereas the difference was not significant in females. Conclusions CHC is associated with increased serum adiponectin independently of age, body mass, diabetes, ADIPOQ genotype, and of severe liver fibrosis, particularly in men.",
keywords = "Adipokines, Adiponectin, Gender, Hepatic fibrosis, Hepatitis C virus, Nonalcoholic fatty liver disease",
author = "Elena Canavesi and Marianna Porzio and Massimiliano Ruscica and Raffaela Rametta and Chiara Macchi and Serena Pelusi and Fracanzani, {Anna Ludovica} and Paola Dongiovanni and Silvia Fargion and Paolo Magni and Luca Valenti",
year = "2015",
month = "10",
day = "1",
doi = "10.1016/j.ejim.2015.08.001",
language = "English",
volume = "26",
pages = "635--639",
journal = "European Journal of Internal Medicine",
issn = "0953-6205",
publisher = "Elsevier B.V.",
number = "8",

}

TY - JOUR

T1 - Increased circulating adiponectin in males with chronic HCV hepatitis

AU - Canavesi, Elena

AU - Porzio, Marianna

AU - Ruscica, Massimiliano

AU - Rametta, Raffaela

AU - Macchi, Chiara

AU - Pelusi, Serena

AU - Fracanzani, Anna Ludovica

AU - Dongiovanni, Paola

AU - Fargion, Silvia

AU - Magni, Paolo

AU - Valenti, Luca

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Background Increased levels of adiponectin, a major adipokine with insulin sensitizing properties showing a strong sexual dimorphism, have been reported in individuals with chronic HCV infection (CHC), but data are limited by small samples and lack of control for the genetic background and hepatic fibrosis. The aim of this study was to compare adiponectin levels between CHC patients and accurately matched controls. Methods We considered 184 CHC patients, matched (1:1) for age, gender, body mass index, and Adiponectin genotype (ADIPOQ) with healthy individuals. To control for the severity of liver disease, a second control group consisting of 95 patients with histological nonalcoholic fatty liver disease (NAFLD) further matched (1:1) for severe fibrosis was exploited. ADIPOQ genotype was evaluated by Taqman assays, serum adiponectin measured by ELISA. Results Serum adiponectin was higher in CHC patients than in healthy individuals (9.0 ± 5.0 μg/ml vs. 7.3 ± 4.0 μg/ml; p = 0.001; adjusted estimate + 1.8, 1.7-2.9; p = 0.001), and than in NAFLD patients (8.3 ± 4.5 μg/ml vs. 6.0 ± 4.2 μg/ml; p <0.001; adjusted estimate + 0.8, 0.2-1.4, p = 0.006). After stratification for sex, serum adiponectin was higher in males with CHC than in healthy individuals and NAFLD patients (p <0.005 for both), whereas the difference was not significant in females. Conclusions CHC is associated with increased serum adiponectin independently of age, body mass, diabetes, ADIPOQ genotype, and of severe liver fibrosis, particularly in men.

AB - Background Increased levels of adiponectin, a major adipokine with insulin sensitizing properties showing a strong sexual dimorphism, have been reported in individuals with chronic HCV infection (CHC), but data are limited by small samples and lack of control for the genetic background and hepatic fibrosis. The aim of this study was to compare adiponectin levels between CHC patients and accurately matched controls. Methods We considered 184 CHC patients, matched (1:1) for age, gender, body mass index, and Adiponectin genotype (ADIPOQ) with healthy individuals. To control for the severity of liver disease, a second control group consisting of 95 patients with histological nonalcoholic fatty liver disease (NAFLD) further matched (1:1) for severe fibrosis was exploited. ADIPOQ genotype was evaluated by Taqman assays, serum adiponectin measured by ELISA. Results Serum adiponectin was higher in CHC patients than in healthy individuals (9.0 ± 5.0 μg/ml vs. 7.3 ± 4.0 μg/ml; p = 0.001; adjusted estimate + 1.8, 1.7-2.9; p = 0.001), and than in NAFLD patients (8.3 ± 4.5 μg/ml vs. 6.0 ± 4.2 μg/ml; p <0.001; adjusted estimate + 0.8, 0.2-1.4, p = 0.006). After stratification for sex, serum adiponectin was higher in males with CHC than in healthy individuals and NAFLD patients (p <0.005 for both), whereas the difference was not significant in females. Conclusions CHC is associated with increased serum adiponectin independently of age, body mass, diabetes, ADIPOQ genotype, and of severe liver fibrosis, particularly in men.

KW - Adipokines

KW - Adiponectin

KW - Gender

KW - Hepatic fibrosis

KW - Hepatitis C virus

KW - Nonalcoholic fatty liver disease

UR - http://www.scopus.com/inward/record.url?scp=84943658807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943658807&partnerID=8YFLogxK

U2 - 10.1016/j.ejim.2015.08.001

DO - 10.1016/j.ejim.2015.08.001

M3 - Article

VL - 26

SP - 635

EP - 639

JO - European Journal of Internal Medicine

JF - European Journal of Internal Medicine

SN - 0953-6205

IS - 8

ER -